Marshall Wace North America L.P. 13D and 13G filings for Acrivon Therapeutics, Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 09:51 am Sale |
2023-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Marshall Wace North America L.P. | 597,469 2.700% |
-625,783 (-51.16%) |
Filing |
| 2023-02-14 09:35 am Purchase |
2022-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV |
Marshall Wace North America L.P. | 1,223,252 5.900% |
1,223,252 (New Position) |
Filing |